{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T16:45:50Z","timestamp":1776530750889,"version":"3.51.2"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T00:00:00Z","timestamp":1547510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.phrs.2019.01.023","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T20:47:03Z","timestamp":1547498823000},"page":"104139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["The long and winding road in pharmaceutical development of canakinumab from rare genetic autoinflammatory syndromes to myocardial infarction and cancer"],"prefix":"10.1016","volume":"154","author":[{"given":"Hermann","family":"Gram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2019.01.023_bib0005","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1359-6101(02)00020-5","article-title":"The balance between IL-1 and IL-1Ra in disease","volume":"13","author":"Arend","year":"2002","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.phrs.2019.01.023_bib0010","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2174\/156802605775009720","article-title":"Caspase inhibitors: a pharmaceutical industry perspective","volume":"5","author":"Linton","year":"2005","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.phrs.2019.01.023_bib0015","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1080\/17512433.2017.1338946","article-title":"Pharmacological treatment options for cryopyrin-associated periodic syndromes","volume":"10","author":"Landmann","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2019.01.023_bib0020","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/nbt1135","article-title":"Human antibodies from transgenic animals","volume":"23","author":"Lonberg","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.phrs.2019.01.023_bib0025","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1186\/ar2438","article-title":"The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis","volume":"10","author":"Alten","year":"2008","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2019.01.023_bib0030","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1080\/19420862.2015.1081323","article-title":"The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1\u03b2","volume":"7","author":"Rondeau","year":"2015","journal-title":"MAbs."},{"key":"10.1016\/j.phrs.2019.01.023_bib0035","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1191\/0960327102ht295oa","article-title":"Feasibility of human trials to assess developmmental immunotoxicity, and some comparison with data on New World monkeys","volume":"21","author":"Neuberta","year":"2002","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.phrs.2019.01.023_bib0040","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11599820-000000000-00000","article-title":"Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1\u03b2 monoclonal antibody","volume":"51","author":"Chakraborty","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2019.01.023_bib0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2474-12-153","article-title":"Efficacy and safety of the human anti-IL-1\u03b2 monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study","volume":"12","author":"Alten","year":"2011","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.phrs.2019.01.023_bib0050","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1055\/s-0030-1265181","article-title":"Analysis of cryopyrin-associated periodic syndromes (CAPS) in German children: epidemiological, clinical and genetic characteristics","volume":"222","author":"Lainka","year":"2010","journal-title":"Klin. P\u00e4diatr."},{"key":"10.1016\/j.phrs.2019.01.023_bib0055","doi-asserted-by":"crossref","first-page":"R86","DOI":"10.1152\/ajpregu.00504.2006","article-title":"Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes","volume":"292","author":"Simon","year":"2007","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.phrs.2019.01.023_bib0060","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1084\/jem.20082481","article-title":"In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes","volume":"206","author":"Lachmann","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.phrs.2019.01.023_bib0065","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome","volume":"360","author":"Lachmann","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.01.023_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbpa.2015.12.003","article-title":"Preclinical characterization and clinical development of ILARIS\u00ae (canakinumab) for the treatment of autoinflammatory diseases","volume":"32","author":"Gram","year":"2016","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.phrs.2019.01.023_bib0075","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade","volume":"201","author":"Pascual","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.phrs.2019.01.023_bib0080","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.01.023_bib0085","series-title":"European Medicines Agency","year":"2018"},{"key":"10.1016\/j.phrs.2019.01.023_bib0090","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/rheumatology\/ken460","article-title":"Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout","volume":"48","author":"Dalbeth","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.phrs.2019.01.023_bib0095","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.4049\/jimmunol.138.10.3213","article-title":"Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1","volume":"138","author":"Di Giovine","year":"1987","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2019.01.023_bib0100","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2019.01.023_bib0105","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.01.023_bib0110","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/ard.2010.144063","article-title":"Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study","volume":"70","author":"Schlesinger","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.01.023_bib0115","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/bor.0000174210.78449.6b","article-title":"Familial autoinflammatory diseases: genetics, pathogenesis and treatment","volume":"17","author":"Stojanov","year":"2005","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.phrs.2019.01.023_bib0120","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1684\/ecn.2009.0163","article-title":"Specific increase in caspase-1 activity and secretion of IL-1 family cytokines: a putative link between mevalonate kinase deficiency and inflammation","volume":"20","author":"Normand","year":"2009","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.phrs.2019.01.023_bib0125","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/ar2197","article-title":"Falling into TRAPS--receptor misfolding in the TNF receptor 1-associated periodic fever syndrome","volume":"9","author":"Kimberley","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2019.01.023_bib0130","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cellimm.2011.02.007","article-title":"Differential cytokine secretion results from p65 and c-Rel NF-\u03baB subunit signaling in peripheral blood mononuclear cells of TNF receptor-associated periodic syndrome patients","volume":"268","author":"Nedjai","year":"2011","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.phrs.2019.01.023_bib0135","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/sj.cdd.4401734","article-title":"Cryopyrin and pyrin activate caspase-1, but not NF-kappaB, via ASC oligomerization","volume":"13","author":"Yu","year":"2006","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.phrs.2019.01.023_bib0140","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"L.L. Yao Hui, V.B. Kraus, Colchicine\u2014update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.01.023_bib0145","first-page":"1540","article-title":"Association of drug transporter gene ABCB1 (MDR1) 3435 C to T polymorphism with colchicine response in familial Mediterranean fever","volume":"34","author":"Tufan","year":"2007","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.phrs.2019.01.023_bib0150","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","article-title":"Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes","volume":"378","author":"De Benedetti","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.01.023_bib0155","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1126\/science.aaa8064","article-title":"Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis","volume":"349","author":"Warnatsch","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.phrs.2019.01.023_bib0160","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1586\/14779072.2016.1128828","article-title":"A focus on inflammation as a major risk factor for atherosclerotic cardiovascular diseases","volume":"14","author":"Gregersen","year":"2016","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.phrs.2019.01.023_bib0165","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5551\/jat.13.21","article-title":"The effect of interleukin-1 receptor antagonist on arteries and cholesterol metabolism","volume":"13","author":"Isoda","year":"2006","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.phrs.2019.01.023_bib0170","first-page":"213","article-title":"Risk factors for heart failure in patients with one prior myocardial infarction episode","volume":"46","author":"Mocan","year":"2008","journal-title":"Rom. J. Intern. Med."},{"key":"10.1016\/j.phrs.2019.01.023_bib0175","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2019.01.023_bib0180","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/s41591-018-0124-5","article-title":"Interleukin-1\u03b2 has atheroprotective effects in advanced atherosclerotic lesions of mice","volume":"24","author":"Gomez","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2019.01.023_bib0185","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.01.023_bib0190","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.01.023_bib0195","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.01.023_bib0200","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cytogfr.2017.06.001","article-title":"Effects of interleukin-1beta polymorphisms on brain function and behavior in healthy and psychiatric disease conditions","volume":"37","author":"Tsai","year":"2017","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.phrs.2019.01.023_bib0205","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin-1 in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.phrs.2019.01.023_bib0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1463-1326.2012.01637.x","article-title":"Effect of anti-IL-1\u03b2 antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial","volume":"14","author":"Rissanen","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2019.01.023_bib0215","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.diabet.2013.07.003","article-title":"Impact of interleukin-1\u03b2 antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: Results of secondary endpoints from a randomized, placebo-controlled trial","volume":"39","author":"Hensen","year":"2013","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.phrs.2019.01.023_bib0220","series-title":"US National Libray of Medicine","year":"2018"},{"key":"10.1016\/j.phrs.2019.01.023_bib0225","first-page":"1","article-title":"Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study","author":"Krause","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.phrs.2019.01.023_bib0230","first-page":"1","article-title":"Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials","volume":"6736","author":"Moran","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.01.023_bib0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2013.04.008","article-title":"Efficacy and safety of canakinumab in urticarial vasculitis: An open-label study","author":"Krause","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.phrs.2019.01.023_bib0240","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/bjd.14037","article-title":"Canakinumab in adults with steroid-refractory pyoderma gangrenosum","volume":"173","author":"Kolios","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.phrs.2019.01.023_bib0245","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.amjcard.2018.07.002","article-title":"Usefulness of canakinumab to improve exercise capacity in patients with chronic systolic heart failure and elevated C-reactive protein","volume":"122","author":"Trankle","year":"2018","journal-title":"Am. J. Cardiol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818319832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818319832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:04:00Z","timestamp":1760911440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661818319832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":49,"alternative-id":["S1043661818319832"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.01.023","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The long and winding road in pharmaceutical development of canakinumab from rare genetic autoinflammatory syndromes to myocardial infarction and cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.01.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104139"}}